S. Cosnier-pucheu
Founder, Chief Scientific Officer
research and the pharmaceutical
Poxel
France
Biography
Dr. Cosnier-Pucheu has more than 23 years’ experience in academic research and the pharmaceutical industry. Before co-founding CILcare, Sylvie headed up an in-vivo pharmacology group working on tinnitus and hearing loss. In the course of this work, she collaborated with a number of highly-regarded academic experts in Hearing Disorders, who are now mentoring the CILcare laboratory team. In addition, Sylvie led scientific teams and developed animal models, mainly in rodents, to support drug discovery and development at Sanofi in the fields of cardiology, oncology, aging and hearing. She also has extensive experience in approaches related to the antioxidant mechanisms, which are part of the investigated pathways in the hearing field. She has always been deeply involved in Animal Well-being and was part of the Ethics Committee of Sanofi for years. Sylvie has a Ph.D in cardiovascular pharmacology from the University of Grenoble. She performed a post-doc in Boston for the company Eukarion and has a degree in clinical development. She is the author of several publications and of a patent. Dr. Cosnier-Pucheu has more than 23 years’ experience in academic research and the pharmaceutical industry. Before co-founding CILcare, Sylvie headed up an in-vivo pharmacology group working on tinnitus and hearing loss. In the course of this work, she collaborated with a number of highly-regarded academic experts in Hearing Disorders, who are now mentoring the CILcare laboratory team. In addition, Sylvie led scientific teams and developed animal models, mainly in rodents, to support drug discovery and development at Sanofi in the fields of cardiology, oncology, aging and hearing. She also has extensive experience in approaches related to the antioxidant mechanisms, which are part of the investigated pathways in the hearing field. She has always been deeply involved in Animal Well-being and was part of the Ethics Committee of Sanofi for years. Sylvie has a Ph.D in cardiovascular pharmacology from the University of Grenoble. She performed a post-doc in Boston for the company Eukarion and has a degree in clinical development. She is the author of several publications and of a patent.
Research Interest
clinical trials in Oncology, Neurology and Psychiatry,project management, industrial strategy and health environment.